AnGes, Inc. (TYO:4563)

Market Cap	20.61B +3.3%
Revenue (ttm)	908.00M +35.9%
Net Income	-4.96B
EPS	-13.21
Shares Out	396.33M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	617,800
Average Volume	1,780,170
Open	52.00
Previous Close	52.00
Day's Range	52.00 - 53.00
52-Week Range	51.00 - 120.00
Beta	0.66
RSI	43.55
Earnings Date	May 15, 2026

About AnGes

AnGes, Inc. engages in the research and development of gene-based medicines. It develops HGF gene therapy product for the treatment of chronic arterial occlusive disease; NF-KB decoy oligonucleotide for chronic discogenic lumbar back pain; and DNA vaccines for the treatment of hypertension, as well as tie2 agonists for COVID-19/ARDS and drugs for chronic hepatitis B. AnGes, Inc. was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. The company was incorporated in 1999 and is headquartered in Ibaraki, Japan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 56
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4563

Financial Performance

In 2025, AnGes's revenue was 874.00 million, an increase of 35.93% compared to the previous year's 643.00 million. Losses were -5.12 billion, -81.79% less than in 2024.